• 1
    Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer. 1972; 30: 382389.
  • 2
    Costa G, Engle RL Jr., Schilling A, et al. Acute Leukemia Group B and the Eastern Cooperative Oncology Group. Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med. 1973; 54: 589599.
  • 3
    Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979; 301: 743748.
  • 4
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer. 1997; 79: 15611567.
  • 5
    Case DC Jr., Lee DJ III, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977; 63: 897903.
  • 6
    Oken MM, Leong T, Lenhard RE Jr., et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999; 86: 957968.
  • 7
    MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis: the Medical Research Council Working Party for Leukaemia in Adults. Lancet. 1992; 339: 200205.
  • 8
    Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol. 1991; 9: 444448.
  • 9
    Blade J, San Miguel JF, Alcala A, et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol. 1993; 11: 11651171.
  • 10
    Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10: 334342.
  • 11
    Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998; 16: 38323842.
  • 12
    Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998; 102: 495502.
  • 13
    Bjorkstrand B, Goldstone AH, Ljungman P, et al, European Group for Bone Marrow Transplantation. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. Leuk Lymphoma. 1994; 15: 265272.
  • 14
    Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995; 13: 13121322.
  • 15
    Sirohi B, Powles R, Mehta J, et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol. 1999; 107: 656666.
  • 16
    Child JA, Morgan GJ, Davies FE, et al, Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 18751883.
  • 17
    Oken MM, Kyle RA, Greipp PR, et al. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2b) in patients with multiple myeloma. Leuk Lymphoma. 1996; 20: 447452.
  • 18
    Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001; 27: 10371043.
  • 19
    Oivanen TM, Kellokumpu-Lehtinen P, Koivisto AM, Koivunen E, Palva I. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol. 1999; 62: 109116.
  • 20
    Riccardi A, Mora O, Tinelli C, et al, Cooperative Group of Study Treatment of Multiple Myeloma. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur J Cancer. 2003; 39: 3137.
  • 21
    Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001; 112: 814819.
  • 22
    Lahuerta JJ, Martinez-Lopez J, de la Serna J, et al, Geth and Pethema Groups. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol. 2000; 109: 438446.
  • 23
    Rajkumar SV, Fonseca R, Dispenzieri A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000; 26: 979983.
  • 24
    Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36: 842854.
  • 25
    Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998; 91: 25012507.
  • 26
    Greipp PR, Witzig TE, Gonchoroff NJ. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Hematol. 1985; 20: 289292.
  • 27
    Kyle RA, Katzmann JA, Lust JA, Dispenzieri A. Immunochemical characterization of immunoglobulins. In: RoseNR, HamiltonRG, DetrickB, editors. Manual of clinical laboratory immunology, 6th ed. Washington, DC: ASM Press, 2002. p 7191.
  • 28
    Billadeau D, Blackstadt M, Greipp P, et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991; 78: 30213029.
  • 29
    Cox DR. The analysis of binary data. London: Methuen, 1970.
  • 30
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 31
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972; 135: 185207.
  • 32
    Peto R, Pike MC, Armitage NE, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 33
    Cox DR, Snell EJ. Analysis of binary data, 2nd ed. New York: Chapman and Hall, 1989.
  • 34
    Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187220.
  • 35
    Ludwig H, Cortelezzi A, Van Camp BGK, et al. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases. Oncology. 1985; 42(Suppl 1): 1925.
  • 36
    Quesada JR, Alexanian R, Hawkins M, et al. Treatment of multiple myeloma with recombinant α-interferon. Blood. 1986; 67: 275278.
  • 37
    Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000; 18: 22732281.
  • 38
    Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999; 17: 208215.
  • 39
    Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998; 91: 35183523.
  • 40
    Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999; 93: 5565.